Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Issue 11 (27th September 2019)

• Record Type: Journal Article
• Authors: Clarke, William T; Papamichael, Konstantinos; Vande Casteele, Niels; Germansky, Katharine A; Feuerstein, Joseph D; Melmed, Gil Y; Siegel, Corey A; Irving, Peter M; Cheifetz, Adam S
• Is Part Of: Inflammatory bowel diseases. Volume 25:Issue 11(2019)
• Page Start: e143
• Page End: e145
• Publication Date: 2019-09-27
• Subjects: Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izz202
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract : This prospective observational study including consecutive patients with inflammatory bowel disease treated with either infliximab or adalimumab showed that although the correlation between the ELISA and the homogeneous mobility shift assay was good for both drugs, the agreement was poor.